trending Market Intelligence /marketintelligence/en/news-insights/trending/gycxgQYPy32Qk5ou9GKweA2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Pfizer receives FDA approval to remove boxed warning on smoking drug

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Pfizer receives FDA approval to remove boxed warning on smoking drug

The U.S. FDA authorized label revisions to Pfizer Inc.'s Chantix.

The pharma giant is no longer required to make boxed warnings regarding serious neuropsychiatric events that lead to anxiety and depression.

Chantix is a prescription medication that helps adults 18 and over to quit smoking. The treatment is considered superior to bupropion or nicotine patches.

The revision may further encourage smokers and healthcare providers to discuss smoking cessation treatment options, Pfizer said in a statement.